Japanese encephalitis virus vaccine (JE-VAX, Ixiaro)
Jump to navigation
Jump to search
Classification
- JE-MB (JE-VAX)
- licensed in 1992
- production discontinued in 2006
- only vaccine available for children
- remaining does reserved for children
- J-VC (IXIARO)[2]
- licensed in 2009
- adults >= 17 years of age
Indications
- active immunization against Japanese encephalitis for
- approved for children as young as 2 months of age[4]
* risk of acquiring Japanese encephalitis is very low for most travelers
- < 1 case per million trips to Asia
Contraindications
- hypersensitivity to JE-VAX, especially manifesting as generalized urticaria or angioedema
- hypersensitivity to rodent proteins or proteins of neural origin
- hypersensitivity to thimerosal
- pregnancy, unless substantial risk of infection
Dosage
- J-VC (IXIARO) licensed in 2009[2]
- adults >= 17 years of age
- two intramuscular injections one month apart
- JE-MB (JE-VAX)
- adults & children > 3 years of age
- three doses of 1 mL on days 0, 7, & 14-30
- last dose 10 days before travel
- booster may be given 2 years after primary immunization
- children 1-3 years of age: 0.5 mL doses
- adults & children > 3 years of age
Adverse effects
- most common (1-10%)
- inflammation at injection site, fever, headache, malaise, rash, chills, dizziness, myalgias, nausea/vomiting, abdominal pain, urticaria, pruritus, hypotension
- uncommon (< 1%)
- anaphylaxis, encephalitis, encephalopathy, seizure, peripheral neuropathy, erythema multiforme, erythema nodosum, angioedema, dyspnea, joint swelling
- adverse effects may occur shortly after or up to 17 days following vaccination
- report allergic or unusual adverse effects to: Vaccine Adverse Event Reporting System (VAERS) (800) 822-7967
Mechanism of action
- both vaccines are inactivated & stimulate production of neutralizing antibody
More general terms
Additional terms
References
- ↑ Kaiser Permanente Northern California Regional Drug Formulary, 1998
- ↑ 2.0 2.1 2.2 Fischer M et al. Japanese encephalitis vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010 Mar 12;59(RR-1):1-27. PMID: https://www.ncbi.nlm.nih.gov/pubmed/20224546 corresponding NGC guideline withdrawn Jan 2016
- ↑ Intercell Announces Pediatric Approval of its Japanese Encephalitis Vaccine in the U.S. Vienna (Austria), May 21, 2013 http://www.intercell.com/main/company/news/news-full/article/intercell-announces-pediatric-approval-of-its-japanese-encephalitis-vaccine-in-the-us/
- ↑ 4.0 4.1 Centers for Disease Control and Prevention Use of Japanese Encephalitis Vaccine in Children: Recommendations of the Advisory Committee on Immunization Practices, 2013. MMWR. November 15, 2013 / 62(45);898-900 http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6245a3.htm
- ↑ 5.0 5.1 Hills SL, Walter EB, Atmar RL, Fischer M. Japanese Encephalitis Vaccine: Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2019;68(No. RR-2):1-33 https://www.cdc.gov/mmwr/volumes/68/rr/rr6802a1.htm